Key Takeaways
- Jefferies upgraded Reckitt (LSE: RKT) on 22 July 2026, moving to a positive stance from a neutral one, lifting its price target to 5,900p, with analyst David Hayes arguing the market has “overly punished” the group for largely one-off setbacks.
- Reckitt shares rose more than 2% on the note to around 5,048p; the target implies roughly mid-teens percentage upside, though brokers remain split on the stock.
- The investment debate hinges on execution: simplifying the portfolio (the completed Essential Home disposal, a mooted Mead Johnson exit) while defending margins and navigating US infant-formula litigation.
- First-quarter 2026 trading disappointed — core like-for-like growth of 1.3% missed expectations and management flagged a first-half margin squeeze — so the 29 July half-year results are a key test.
- This article is analysis and reporting only, not advice; nothing here constitutes personal financial advice regarding Reckitt (LSE: RKT).
Reckitt (LSE: RKT), the FTSE 100 consumer-health and hygiene group behind Dettol, Durex, Nurofen, Strepsils, Gaviscon, Finish and Vanish, has spent much of the past two years as a battleground stock. A profit-warning in 2024, a US infant-formula lawsuit hanging over its Mead Johnson nutrition arm, and a sweeping plan to slim the company down have left the shares trading well below the premium rating consumer-staples investors once paid for its brands.
So a broker upgrade lands with more weight than usual. On 22 July 2026 — reported in the London broker-ratings digests as “Deutsche Bank cuts Mitie, Jefferies ups Reckitt” — Jefferies moved Reckitt to a more positive rating and raised its price target. The timing is pointed: half-year results are due on 29 July, and a US jury verdict on the infant-formula litigation is expected soon after. This piece verifies exactly what Jefferies did, sets it against Reckitt's recent numbers and strategy, and asks whether the pieces are in place for a genuine re-rating — the market awarding a higher valuation multiple to the same earnings.
The Jefferies Upgrade — and the Re-Rating Question
The specifics, per reporting of the note dated 22 July 2026: Jefferies analyst David Hayes upgraded Reckitt, moving to a positive stance from a neutral one, and set a price target of 5,900p (raised from 5,600p, according to AskTraders). The shares reacted positively, climbing more than 2% to around 5,048p against a prior close near 4,938p. On that share price, the target implies upside of roughly 17% before dividends — meaningful, but not heroic.
Hayes's core argument is that “the market has overly punished Reckitt for a series of largely one-off setbacks.” He attributed the weak first quarter to three discrete events: changes to Russian sanctions rules (a roughly £26m revenue impact), Chinese regulatory action on intimate-wellness products including VAT on condoms (about £12m), and an unusually weak cold-and-flu season (down around 10% year on year). Strip those out, the note contends, and the rest of the business grew around 5% — much closer to Reckitt's medium-term ambition.
Two forward catalysts feature in the thesis. First, the 29 July half-year results are framed as a potential “clearing event” — a moment where management may reset guidance downward, removing an overhang and letting the shares trade on cleaner numbers. Second, an anticipated US jury verdict in the Mead Johnson infant-formula litigation, expected in late August, could remove or reduce a source of investor anxiety depending on the outcome.
It is worth stressing what an upgrade is and is not. A broker rating is one firm's opinion, not a fact about the business, and Reckitt's own analyst coverage is divided: other houses have kept more cautious stances, with Berenberg, for example, keeping a neutral stance and a lower target after the first quarter, citing “limited near-term visibility.” A re-rating requires the wider market — not one broker — to gain confidence that Reckitt's growth and margins are durable. Jefferies is effectively betting that the bad news is now transitory and largely in the price. Whether that proves right depends on execution, and on events partly outside the company's control.
Recent Financial Performance
The starting point is Reckitt's full-year 2025 results, published on 5 March 2026. Group net revenue was £14,205m, up 0.3% on a reported (IFRS) basis but 5.0% on a like-for-like basis — the measure that strips out currency moves, acquisitions and disposals to show underlying volume and price growth. “Core Reckitt”, the continuing business the group wants to build around, grew 5.2% like-for-like, led by emerging markets at +14.6%.
Profitability held up. Adjusted operating profit was £3,543m, up 5.3% at constant currency, with the adjusted operating margin at 24.9% — an improvement of about 40 basis points (0.4 percentage points) year on year. The reported (IFRS) operating profit jumped to £4,217m, but that figure was flattered by a one-off gain on the Essential Home disposal and so overstates the underlying trend.
Cash generation was the softer spot. Free cash flow — the cash left after running the business and investing in it — fell 23.4% to £1,709m, dragged down by restructuring costs and a higher tax bill. Net debt stood at £6,558m, or about 1.6 times adjusted EBITDA, a comfortable-but-not-pristine level of borrowing for a company of Reckitt's cash-generative profile.
On shareholder returns, the regular dividend rose 5.0% to 212.2p, and the company bought back £879m of its own shares over the year. Separately, it paid a special dividend of 235p per share in February 2026, funded from the Essential Home sale proceeds — a one-off return of roughly £1.6bn to investors.
The tone changed at the first quarter. On 22 April 2026, Reckitt reported core like-for-like growth of just 1.3% — well short of the roughly 2.9% analysts had penned in — with group like-for-like at 0.6%. Emerging markets again did the heavy lifting at +7.6%. Crucially, management warned that first-half adjusted operating margin would be “around 200 basis points lower” than a year earlier, blaming higher oil prices (a feedstock and packaging cost) and the weak seasonal demand that hit Mucinex, Strepsils and Nurofen. The shares fell 5-7% on the day to their lowest since late 2024. Full-year guidance was, however, reiterated — the source of the market's subsequent tug-of-war over whether the setback is temporary.
Strategy and Operations
The strategic story is one of deliberate simplification. In 2024-25 Reckitt set out to concentrate on higher-margin, faster-growing consumer-health and hygiene “Powerbrands” — Dettol, Lysol, Durex, Nurofen, Gaviscon, Strepsils, Mucinex, Finish and others — while separating out slower, more commoditised or higher-risk businesses.
The largest completed step is the Essential Home disposal — the portfolio of home-care and laundry brands such as Air Wick, Cillit Bang, Mortein and Calgon. Reckitt agreed to divest the unit and completed the transaction on 31 December 2025 for around £2.2bn of net consideration, booking a pre-tax gain of roughly £1.2bn and retaining a 30% stake in the acquiring vehicle backed by buyout house Advent. Those proceeds funded the special dividend. The prize is a cleaner, higher-margin group; the risk is “stranded costs” — overheads that stay behind once a business leaves — which management aims to offset through its “Fuel for Growth” efficiency programme.
The second, unfinished step is Mead Johnson, the US-centric infant-nutrition business Reckitt bought in 2017. In 2025 the group signalled it was reviewing options, up to and including a sale or separation. Mead Johnson grew 3.8% like-for-like in 2025 to £2,119m as it recovered from a 2024 tornado that disrupted a key plant, but 2026 guidance points to only low-single-digit growth. As of mid-2026 the company was still “assessing options” for an exit — and, critically, any buyer must weigh the litigation attached to it.
That litigation is the biggest overhang. Mead Johnson faces US lawsuits alleging its preterm-infant formula contributed to necrotizing enterocolitis (NEC), a serious bowel condition in premature babies. Around 810 federal cases are consolidated in a multidistrict litigation in the Northern District of Illinois, with hundreds more in state courts. Outcomes have been mixed for the defendants: a $60m verdict against Mead Johnson in March 2024 is under appeal, while a St. Louis jury returned a defence verdict in Mead Johnson's favour on 6 July 2026. Further bellwether trials — test cases that help gauge the litigation's direction — are scheduled, including a federal trial in August 2026. Reckitt's own accounts state that potential costs “are not considered probable and cannot be reliably estimated at the current time”, meaning no large provision sits on the balance sheet — a stance that supports reported profit but leaves the ultimate exposure genuinely uncertain.
Underpinning all of this is continued brand investment. Reckitt has been clear it intends to keep spending on marketing and innovation — Durex's “Intensity” launch and Dettol's expansion are cited successes — which is supportive of LSEg-term share but, as Jefferies and others note, caps how quickly margins can expand.
Sector and Macro Context
Reckitt's fortunes are also being shaped by where the wider market is looking. Early 2026 saw a rotation into consumer staples as investors trimmed richly valued technology exposure: the US staples benchmark (the XLP fund) rose around 13% year-to-date by early February against a roughly 3% decline for tech, on concerns about a softening jobs market, sticky inflation and geopolitical risk. Staples appeal because they provide everyday necessities, generate recurring revenue and pay dependable dividends — typically 3-4% yields — with valuations in the high-teens to low-20s on forward earnings.
That backdrop is a mild tailwind for a defensive name like Reckitt, but it is not a rescue. Peers such as Haleon, Unilever and Nestlé compete for the same defensive capital, and Reckitt must earn its place by proving the growth and margin resilience that justify a premium. A rising tide lifts the sector; it does not settle a US courtroom or fix a weak cold-and-flu season.
Growth Drivers
The bull case rests on several levers. Emerging markets are the standout, compounding at double digits and now a materially larger slice of the mix. The health portfolio — Nurofen, Gaviscon, Strepsils, Mucinex — benefits from ageing populations and self-care trends, while hygiene brands Dettol and Lysol retain high household penetration. Portfolio simplification should lift the group's structural growth rate and margin, and the “Fuel for Growth” cost programme provides a self-help lever independent of the top line. If the one-off drags of early 2026 do prove transitory, the ~5% underlying growth Jefferies points to would support the re-rating thesis.
Material Risks
Against that sit real risks. The infant-formula litigation is the clearest: an adverse run of verdicts, or a large settlement, could be financially and reputationally material, and complicates any Mead Johnson sale. Disposal execution is a second risk — separations are costly and distracting, stranded costs can linger, and a weak market may mean a disappointing price for nutrition. Input costs and FX are a third: higher oil prices are already pressuring first-half margins, and as a global earner Reckitt is exposed to sterling swings. Finally, demand risk — soft European consumers and another mild respiratory season — would undercut the recovery narrative and test the reiterated guidance.
The Investment Case, Balanced
Separating the strands is essential. As fact: Reckitt grew 5% like-for-like in 2025 at a near-25% margin, completed the Essential Home sale, returned cash via a special dividend and buyback, and then missed first-quarter expectations while flagging a first-half margin squeeze. As broker opinion: Jefferies believes the recent weakness is largely one-off and the shares are too cheap, hence its positive rating and 5,900p target; Berenberg and others are less convinced and stay neutral. As our analysis: the re-rating logic is coherent but front-loaded on events not yet delivered — a clean half-year print on 29 July, a benign litigation path, and evidence that emerging-markets strength can offset European softness. The valuation has de-rated enough that positive surprises could be rewarded, but the same set-up means disappointments would likely be punished.
Three Scenarios
Constructive Scenario
The 29 July results confirm the first-quarter drags were transitory; core growth reaccelerates toward the 4-5% range; margins stabilise as oil costs ease and “Fuel for Growth” bites. Litigation newsflow stays neutral-to-favourable and a Mead Johnson resolution emerges at an acceptable price. Readers re-rate the cleaner, health-focused group closer to staples peers, and Jefferies' 5,900p target looks achievable.
Base Scenario
Growth recovers gradually rather than sharply; margins remain under near-term pressure before improving; litigation grinds on with mixed verdicts and no global settlement. The shares trade in a range, supported by the dividend and buyback but capped by uncertainty — a “show me” stock where progress is real but slow.
Downside Scenario
Consumer softness persists, another weak season and sticky input costs squeeze margins further, and an adverse litigation development or a poorly received Mead Johnson outcome revives the overhang. Guidance is cut more than expected, and the shares de-rate again — the risk inherent in a recovery story that has not yet proven itself.
Outlook
Reckitt (LSE: RKT) enters its 29 July half-year results at an inflection point. Jefferies' 22 July upgrade to a more positive stance, with a target of 5,900p, crystallises the bull case: a fundamentally strong stable of health and hygiene brands, a cleaner post-Essential Home portfolio, and a share price that has arguably over-discounted a run of one-off setbacks. The bear case is equally clear: unproven margin recovery, unresolved US infant-formula litigation, and the execution risk of a Mead Johnson exit. A genuine re-rating of Reckitt (LSE: RKT) is plausible, but it is not yet earned — it depends on the numbers on 29 July, the courtroom in the weeks after, and the durability of emerging-markets growth. For now, the fresh broker boost sharpens the question rather than answering it. Nothing here constitutes personal financial advice; readers should form their own view or seek regulated advice.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...